Iris Schrader

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Carsten Denkert, Sibylle Loibl, Aurelia Noske et al. · Journal of Clinical Oncology · 2009 · 1.8K citations

Breast Oncology, Immunology, Pathology +17

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai et al. · New England Journal of Medicine · 2012 · 528 citations

Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

Sabine Riethdorf, Volkmar Müller, Liling Zhang et al. · Clinical Cancer Research · 2010 · 487 citations

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

Yasmin Issa-Nummer, Silvia Darb‐Esfahani, Sibylle Loibl et al. · PLoS ONE · 2013 · 223 citations · Full text

Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

B. Gerber, Sibylle Loibl, Holger Eidtmann et al. · Annals of Oncology · 2013 · 151 citations · Full text

Breast Oncology, Gbg 44, Geparquinto Study +10